Generic Abilify Maintena Availability
Last updated on Apr 10, 2025.
See also: Generic Abilify, Generic Abilify Asimtufii
Abilify Maintena is a brand name of aripiprazole, approved by the FDA in the following formulation(s):
ABILIFY MAINTENA KIT (aripiprazole - for suspension, extended release;intramuscular)
-
Manufacturer: OTSUKA PHARM CO LTD
Approval date: February 28, 2013
Strength(s): 300MG/VIAL [RLD], 400MG/VIAL [RLD] -
Manufacturer: OTSUKA PHARM CO LTD
Approval date: September 29, 2014
Strength(s): 300MG [RLD], 400MG [RLD]
Is there a generic version of Abilify Maintena available?
No. There is currently no therapeutically equivalent version of Abilify Maintena available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Abilify Maintena. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Patent 10,525,057
Issued: January 7, 2020
Inventor(s): Raoufinia Arash
Assignee(s): Otsuka Pharmaceutical Co., Ltd.The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Patent expiration dates:
- March 8, 2034✓
- March 8, 2034✓
- March 8, 2034✓
- March 8, 2034
-
Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Patent 10,980,803
Issued: April 20, 2021
Inventor(s): Raoufinia; Arash
Assignee(s): Otsuka Pharmaceutical Co., Ltd. (Rockville, MD)The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Patent expiration dates:
- September 24, 2033✓
- September 24, 2033✓
- September 24, 2033
-
Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Patent 11,154,553
Issued: October 26, 2021
Inventor(s): Raoufinia Arash
Assignee(s): Otsuka Pharmaceutical Co., Ltd.The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Patent expiration dates:
- September 24, 2033✓
- September 24, 2033✓
- September 24, 2033✓
- September 24, 2033
-
Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Patent 11,344,547
Issued: May 31, 2022
Inventor(s): Raoufinia; Arash
Assignee(s): Otsuka Pharmaceutical Co., Ltd. (Rockville, MD)The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Patent expiration dates:
- September 24, 2033✓
- September 24, 2033✓
- September 24, 2033✓
- September 24, 2033
-
Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function
Patent 11,400,087
Issued: August 2, 2022
Inventor(s): Raoufinia; Arash
Assignee(s): Otsuka Pharmaceutical Co., Ltd. (Rockville, MD)The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Patent expiration dates:
- September 24, 2033✓
- September 24, 2033✓
- September 24, 2033✓
- September 24, 2033
-
Medical device containing a cake composition comprising aripiprazole as an active ingredient, and a cake composition comprising aripiprazole as an active ingredient
Patent 11,648,347
Issued: May 16, 2023
Inventor(s): Hiraoka; Shogo et al.
Assignee(s): Otsuka Pharmaceutical Co., Ltd. (Tokyo, JP)The present invention provides a medical device containing a cake composition comprising aripiprazole as an active ingredient and capable of suppressing agglomeration of aripiprazole in a suspension obtained by resuspending a freeze-dried substance; and a cake composition comprising aripiprazole as an active ingredient. The present invention relates to a medical device containing, in a storage container whose inner wall is treated with silicone, a freeze-dried cake composition comprising separately prepared aripiprazole as an active ingredient, wherein there is a space between the inner wall and the cake composition; and a cake composition comprising aripiprazole as an active ingredient and having a strength of 5 to 100 N.
Patent expiration dates:
- April 6, 2034✓
- April 6, 2034
-
Methods for administering aripiprazole
Patent 8,338,427
Issued: December 25, 2012
Inventor(s): Brown Josiah
Assignee(s): Alkermes, Inc.The present invention relates, in part, to the discovery that a pharmaceutical composition comprising aripiprazole and a carrier administered in a bolus injection resulted in an extended release profile similar to that obtained by the injection of a poly lactide-co-glycolide microsphere formulation containing the active agent. This surprising result suggests that pharmacologically beneficial extended release formulations without the complexities and expense associated with the manufacture microspheres.
Patent expiration dates:
- March 15, 2025✓✓
- March 15, 2025✓✓
- March 15, 2025
-
Low hygroscopic aripiprazole drug substance and processes for the preparation thereof
Patent 8,399,469
Issued: March 19, 2013
Inventor(s): Bando Takuji & Aoki Satoshi & Kawasaki Junichi & Ishigami Makoto & Taniguchi Youichi & Yabuuchi Tsuyoshi & Fujimoto Kiyoshi & Nishioka Yoshihiro & Kobayashi Noriyuki & Fujimura Tsutomu & Takahashi Masanori & Abe Kaoru & Nakagawa Tomonori & Shinhama Koichi & Utsumi Naoto & Tominaga Mic
Assignee(s): Otsuka Pharmaceutical Co., Ltd.The present invention provides low hygroscopic forms of aripiprazole and processes for the preparation thereof which will not convert to a hydrate or lose their original solubility even when a medicinal preparation containing the anhydrous aripiprazole crystals is stored for an extended period.
Patent expiration dates:
- June 29, 2025✓
- June 29, 2025
More about Abilify Maintena (aripiprazole)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (69)
- Drug images
- Latest FDA alerts (5)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: atypical antipsychotics
- Breastfeeding
Patient resources
Other brands
Aristada, Abilify Asimtufii, Abilify Discmelt, Aristada Initio
Professional resources
Other brands
Aristada, Abilify Asimtufii, Opipza, Aristada Initio
Other formulations
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
